Preprocedural Neutrophil to Albumin Ratio Predicts In-Stent Restenosis Following Carotid Angioplasty and Stenting

J Stroke Cerebrovasc Dis. 2019 Sep;28(9):2442-2447. doi: 10.1016/j.jstrokecerebrovasdis.2019.06.027. Epub 2019 Jul 12.

Abstract

Background and purpose: In-stent restenosis (ISR) is unfavorable to the long-term efficacy of carotid angioplasty and stenting (CAS). Inflammation plays a critical role in the development of ISR. The aim of the study was to investigate whether neutrophil to albumin ratio (NAR) is a predictor of ISR in patients undergoing CAS.

Methods: We retrospectively recruited patients who underwent CAS. These patients were divided into restenosis group and nonrestenosis group. NAR was examined prior to the CAS procedure. Clinical and radiographic assessments were performed at 6 months and annually after the procedure. ISR was defined as greater than or equal to 50% stenosis in the treated lesion. Cox regression was used to identify predictors of ISR following CAS.

Results: During a mean follow-up period of 14.6 months, a total of 459 treated arteries (in 427 participants) were enrolled, among which 72 (15.7%) developed ISR. On multivariate analysis, baseline NAR greater than or equal to13.4, residual stenosis, lesion length, and baseline glucose level were associated with ISR (hazard ratio 1.94[95% confidence interval (CI), 1.08-3.49], 1.09[95% CI, 1.07-1.12], 1.04[95% CI, 1.01-1.06], and 1.01[95% CI, 1.00-1.02], respectively).

Conclusion: Elevated preprocedural NAR may be a predictor of ISR in patients undergoing CAS.

Keywords: Angioplasty; Neutrophil to albumin ratio; Restenosis; Stenting.

MeSH terms

  • Aged
  • Angioplasty / adverse effects*
  • Angioplasty / instrumentation*
  • Biomarkers / blood
  • Carotid Stenosis / blood
  • Carotid Stenosis / diagnostic imaging
  • Carotid Stenosis / therapy*
  • Female
  • Humans
  • Leukocytes
  • Male
  • Middle Aged
  • Neutrophils*
  • Predictive Value of Tests
  • Recurrence
  • Registries
  • Retrospective Studies
  • Risk Assessment
  • Risk Factors
  • Serum Albumin, Human / analysis*
  • Stents*
  • Time Factors
  • Treatment Outcome

Substances

  • Biomarkers
  • Serum Albumin, Human